Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

While RSV isn’t any more virulent than the cold, flu or COVID, the same precautions are recommended in order to control its ...

As of Jan. 20, the CDC reports that RSV activity has peaked in most of the U.S., particularly among young children—a group ...

U.S. surges of COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus have collectively been dubbed a ...

The U.S. is seeing a "quad-demic" as cases of COVID-19, flu, RSV and norovirus spread at the same time. Experts said this is ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t afford to pay $350 for a one-off vaccine.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...

UPMC saw an increase in RSV cases in its health system, including in Lancaster County, a spokesperson said Jan. 7, especially ...

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.